300122 智飞生物
已收盘 04-13 15:00:00
资讯
新帖
简况
智飞生物与默沙东调整合作协议：取消千亿保底采购，转向弹性模式
中国经营报 · 04-07
智飞生物与默沙东调整合作协议：取消千亿保底采购，转向弹性模式
智飞生物（300122）披露与默沙东调整战略合作协议，4月3日股价下跌2.23%
证券之星 · 04-03
智飞生物（300122）披露与默沙东调整战略合作协议，4月3日股价下跌2.23%
智飞生物修订与默沙东协议 “五连板”津药药业称无在研创新药
财闻 · 04-02
智飞生物修订与默沙东协议 “五连板”津药药业称无在研创新药
智飞生物最新公告：与默沙东调整战略合作协议
证券之星 · 04-02
智飞生物最新公告：与默沙东调整战略合作协议
智飞生物宣布与默克公司调整战略合作协议
美股速递 · 04-02
智飞生物宣布与默克公司调整战略合作协议
股市必读：智飞生物（300122）3月27日董秘有最新回复
证券之星 · 03-30
股市必读：智飞生物（300122）3月27日董秘有最新回复
智飞生物：预防类管线人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗处于上市申报阶段
证券之星 · 03-27
智飞生物：预防类管线人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗处于上市申报阶段
智飞生物：宸安生物的司美格鲁肽注射液（减重）正处于III期临床试验阶段
证券之星 · 03-27
智飞生物：宸安生物的司美格鲁肽注射液（减重）正处于III期临床试验阶段
智飞生物：公司以“技术&市场”双轮驱动发展
证券之星 · 03-27
智飞生物：公司以“技术&市场”双轮驱动发展
智飞生物（300122）披露吸附破伤风疫苗进入Ⅰ/Ⅲ期临床试验公告，3月26日股价下跌2.18%
证券之星 · 03-26
智飞生物（300122）披露吸附破伤风疫苗进入Ⅰ/Ⅲ期临床试验公告，3月26日股价下跌2.18%
智飞生物（300122）披露吸附无细胞百白破（组分）b型流感嗜血杆菌（结合）联合疫苗进入Ⅰ期临床试验公告，3月24日股价上涨2.23%
证券之星 · 03-24
智飞生物（300122）披露吸附无细胞百白破（组分）b型流感嗜血杆菌（结合）联合疫苗进入Ⅰ期临床试验公告，3月24日股价上涨2.23%
股市必读：智飞生物（300122）3月20日董秘有最新回复
证券之星 · 03-23
股市必读：智飞生物（300122）3月20日董秘有最新回复
智飞生物：公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作
证券之星 · 03-20
智飞生物：公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作
智飞生物（300122）披露控股股东部分股份质押公告，3月17日股价下跌0.73%
证券之星 · 03-17
智飞生物（300122）披露控股股东部分股份质押公告，3月17日股价下跌0.73%
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准
智通财经 · 03-16
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准
智飞生物：截至2026年3月10日，公司普通股股东人数为123603
证券之星 · 03-13
智飞生物：截至2026年3月10日，公司普通股股东人数为123603
智飞生物：宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组
证券之星 · 03-13
智飞生物：宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组
“真金白银”显诚意：代表委员热议如何增强投资者“获得感”
21世纪经济报道 · 03-06
“真金白银”显诚意：代表委员热议如何增强投资者“获得感”
智飞生物：人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段
证券之星 · 03-06
智飞生物：人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段
智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理
智通财经 · 03-03
智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":15.48,"timestamp":1776063798000,"preClose":15.73,"halted":0,"volume":16222851,"delay":0,"changeRate":-0.0159,"floatShares":1414000000,"shares":2394000000,"eps":-0.5592,"marketStatus":"已收盘","change":-0.25,"latestTime":"04-13 15:00:00","open":15.65,"high":15.74,"low":15.41,"amount":252000000,"amplitude":0.021,"askPrice":15.49,"askSize":915,"bidPrice":15.48,"bidSize":130,"shortable":0,"etf":0,"ttmEps":-0.5592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776130200000},"marketStatusCode":5,"adr":0,"adjPreClose":15.73,"symbolType":"stock","openAndCloseTimeList":[[1776043800000,1776051000000],[1776056400000,1776063600000]],"highLimit":17.3,"lowLimit":14.16,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.28,"roa":"--","roe":"--","epsLYR":0.8427,"committee":-0.277102,"marketValue":37056000000,"turnoverRate":0.0115,"status":1,"floatMarketCap":21893000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2625959109","title":"智飞生物与默沙东调整合作协议：取消千亿保底采购，转向弹性模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2625959109","media":"中国经营报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625959109?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:19","pubTimestamp":1775571594,"startTime":"0","endTime":"0","summary":"日前，智飞生物（300122.SZ）发布公告称，公司与美国默沙东药厂有限公司签署《经修订和重述的供应、经销与共同推广协议》，对双方于2023年1月21日签署的原协议进行全面修订并予以重述，新协议自签署之日起生效，原协议同步终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604073696779216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765489.SGD","LU1571399168.USD","LU0265550359.USD","LU1699723380.USD","SG9999002232.USD","LU1941712264.USD","LU0006306889.USD","LU1934455863.HKD","LU2361045086.USD","BK0188","LU2361044949.HKD","LU1057294990.SGD","SG9999013999.USD","LU0266013472.USD","LU1974910355.USD","LU0942090050.USD","BK0196","LU1989772840.SGD","LU0130517989.USD","LU0432979614.USD","IE000M9KFDE8.USD","LU1066053197.SGD","IE00B1BXHZ80.USD","LU0238689110.USD","LU1989772923.USD","SG9999014575.USD","IE00BN8TJ469.HKD","IE00BLSP4239.USD","300122","LU0208291251.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1093756325.SGD","LU1201861249.SGD","BK4550","IE00BFTCPJ56.SGD","LU1929549753.HKD","LU2461242641.AUD","BK0046","LU0289739699.SGD","LU2580892789.USD","LU0058720904.USD","BK4007","LU2112291526.USD","SG9999015341.SGD","BK4559","SG9999014542.SGD","LU0965509101.SGD","LU1037948541.HKD","BK4588","LU1023059063.AUD","LU2125154778.USD","LU0122379950.USD","LU2468319806.SGD","BK4585","LU2089984988.USD","LU1064130708.USD","IE00BSNM7G36.USD","LU0648001328.SGD","LU1064131003.USD","LU0098860793.USD","BK4516","LU0965508806.USD","LU2324357040.USD","LU0106261372.USD","BK4534","LU0980610538.SGD","BK4533","LU1941712348.USD","SG9999015358.SGD","SG9999001440.SGD","LU2580892862.HKD","LU0985320562.USD","LU2023250504.SGD","LU2361044865.SGD","MRK","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1066051225.USD","LU0203347892.USD","SG9999001176.SGD","LU1035773651.USD","LU2106854487.HKD","IE00B4R5TH58.HKD","LU1328615791.USD","LU1116320901.HKD","LU1989771016.USD","LU0265550946.USD","LU2023250843.SGD","SG9999002224.SGD","IE00B2B36J28.USD","LU1162221912.USD","LU0130102774.USD","LU1037948897.HKD","BK0239","LU0868494708.USD","LU2148510915.USD","LU0965509010.AUD","LU1934455277.USD","SG9999014567.USD","LU0320765646.SGD","LU1066051811.HKD","LU1585245621.USD","LU1061106388.HKD","LU1430594728.SGD","LU0868494617.USD","LU0211331839.USD","LU0861579265.USD","LU0203345920.USD","IE00BLSP4452.SGD","LU2360032135.SGD","LU1934455194.USD","BK0077","SGXZ57979304.SGD","LU1116320737.USD","LU2125154935.USD","LU0070302665.USD","LU1069347547.HKD","IE0009355771.USD","LU1066051498.USD","LU1983299246.USD","LU1917777945.USD","IE00BJJMRZ35.SGD","LU0477156953.USD","LU1093756168.USD","IE0002141913.USD","SG9999014559.SGD","LU0234572021.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668214","title":"智飞生物（300122）披露与默沙东调整战略合作协议，4月3日股价下跌2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668214?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:07","pubTimestamp":1775225235,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，智飞生物报收于15.33元，较前一交易日下跌2.23%，最新总市值为366.97亿元。公司于近日披露《关于与默沙东调整战略合作协议的公告》。公告显示，重庆智飞生物制品股份有限公司与默沙东于2026年4月2日签署《经修订和重述的供应、经销与共同推广协议》，取代双方2023年1月21日签署的原协议。默沙东将向智飞生物供应九价HPV疫苗、五价轮状病毒疫苗、23价肺炎疫苗，智飞生物在中国大陆地区独家进口、经销和共同推广上述产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","LU1328615791.USD","BK0239","LU2580892789.USD","300122","BK0188","LU1064130708.USD","BK0196","LU2148510915.USD","BK0077","LU1064131003.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624047555","title":"智飞生物修订与默沙东协议 “五连板”津药药业称无在研创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2624047555","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624047555?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:20","pubTimestamp":1775136000,"startTime":"0","endTime":"0","summary":"默沙东授权公司按照协议约定，独家在中国大陆地区以默沙东商标进口、共同推广、经销和销售协议产品的权利。新协议不再约定协议产品的基础采购金额，公司与默沙东将根据市场预期需求和实际接种情况，协商确认预期采购与供应计划，公司据此滚动采购协议产品。本协议的签署深化了公司与默沙东的战略伙伴关系，有利于增强双方对市场变化的协同应对能力，减轻公司的经营压力并降低风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-02/doc-inhtcnfs0882895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4534","BK4007","IE00BJT1NW94.SGD","LU0070302665.USD","LU2089984988.USD","LU1023059063.AUD","LU0234572021.USD","LU0208291251.USD","LU1057294990.SGD","SG9999014542.SGD","LU1066051498.USD","SG9999014575.USD","SG9999001176.USD","BK0188","LU2361044949.HKD","BK1574","LU1061106388.HKD","SG9999001440.SGD","BK4550","LU0058720904.USD","LU1066051225.USD","BK0012","LU2023250504.SGD","IE0009355771.USD","LU1037948897.HKD","IE00BFTCPJ56.SGD","LU0203345920.USD","300122","LU0320765646.SGD","LU1941712348.USD","LU1983299246.USD","LU0320765489.SGD","600488","LU1116320737.USD","BK1161","LU1974910355.USD","LU1037948541.HKD","IE00B4R5TH58.HKD","LU1989772923.USD","LU0477156953.USD","BK0239","LU2461242641.AUD","LU1064130708.USD","LU0965508806.USD","LU0985320562.USD","LU1064131003.USD","SG9999015358.SGD","BK4585","LU0965509010.AUD","BK0077","LU0868494708.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU0265550946.USD","LU0130517989.USD","LU2361045086.USD","BK4559","LU0965509101.SGD","LU1328615791.USD","SGXZ57979304.SGD","LU2580892789.USD","LU2125154778.USD","LU1929549753.HKD","LU0122379950.USD","BK4533","LU0238689110.USD","SG9999014567.USD","LU1162221912.USD","LU2148510915.USD","LU1093756168.USD","SG9999015341.SGD","LU0203347892.USD","LU1941712264.USD","LU0211331839.USD","SG9999001176.SGD","SG9999013999.USD","BK0028","LU1917777945.USD","IE00B2B36J28.USD","LU0098860793.USD","LU1201861249.SGD","LU2360032135.SGD","SG9999002232.USD","IE00BN8TJ469.HKD","LU0130102774.USD","LU2106854487.HKD","LU0861579265.USD","BK4516","LU2468319806.SGD","IE00B1BXHZ80.USD","LU2361044865.SGD","LU1699723380.USD","BK0102","LU1066051811.HKD","LU1291159041.SGD","IE000M9KFDE8.USD","LU1934455863.HKD","LU2112291526.USD","IE00BLSP4452.SGD","LU2125154935.USD","LU1585245621.USD","LU0006306889.USD","LU1093756325.SGD","LU1116320901.HKD","LU0266013472.USD","LU2324357040.USD","LU1989772840.SGD","LU0942090050.USD","BK0046","LU2580892862.HKD","LU1035773651.USD","LU1571399168.USD","LU1069347547.HKD","LU0965509283.SGD","LU0289739699.SGD","SG9999002224.SGD","SG9999014559.SGD","BK4588","LU2023250843.SGD","LU0980610538.SGD","LU0265550359.USD","IE00BLSP4239.USD","BK0196","IE0002141913.USD","LU0432979614.USD","LU0648001328.SGD","LU0868494617.USD","LU1934455194.USD","LU0106261372.USD","LU1934455277.USD","LU1989771016.USD","LU1066053197.SGD","IE00BBT3K403.USD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506146","title":"智飞生物最新公告：与默沙东调整战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506146","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624506146?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:00","pubTimestamp":1775131244,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司与美国默沙东药厂有限公司于2026年4月2日签署《经修订和重述的供应、经销与共同推广协议》，原协议自新协议生效之日起终止。新协议约定默沙东向公司供应九价HPV疫苗等三款产品，授权公司独家在中国大陆进口、推广及销售；不再约定基础采购金额，改为根据市场需求动态协商采购计划。合作期限至2028年12月31日，可延长两年。本次调整有助于深化双方战略合作，增强抗风险能力，减轻经营压力，对公司业务独立性无影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200037156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","LU1328615791.USD","LU2580892789.USD","BK0188","300122","BK0239","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD","BK0077","BK0196","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120376221","title":"智飞生物宣布与默克公司调整战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1120376221","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120376221?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:57","pubTimestamp":1775131049,"startTime":"0","endTime":"0","summary":"智飞生物今日发布公告称，公司已与跨国药企默克公司就双方原有的战略合作协议进行了调整。此次协议调整涉及合作条款的优化，旨在适应当前市场环境与业务发展需求。智飞生物表示，协议的修订将有助于进一步提升合作效率，深化双方在生物医药领域的战略伙伴关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328615791.USD","BK0188","LU2580892862.HKD","LU2580892789.USD","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0077","BK0046","300122","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623368557","title":"股市必读：智飞生物（300122）3月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2623368557","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623368557?lang=zh_cn&edition=full","pubTime":"2026-03-30 04:26","pubTimestamp":1774815972,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，智飞生物报收于15.12元，上涨2.3%，换手率1.15%，成交量16.27万手，成交额2.43亿元。投资者： 请问董秘，26年3月20日司美格鲁肽专利到期，各大药厂都在争分夺秒的加快相关仿制药品上市，但他们的产品属于仿制药品，没有减重作用，也占领不了庞大的减肥市场！！！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000000951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","BK0077","BK0046","BK0196","LU1064130708.USD","300122","BK0188","LU1064131003.USD","LU1328615791.USD","LU2580892862.HKD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622362847","title":"智飞生物：预防类管线人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗处于上市申报阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2622362847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622362847?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:45","pubTimestamp":1774604709,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物03月27日在投资者关系平台上答复投资者关心的问题。明明是你们对趋势的误判，带来了这么严重的后果智飞生物回复：您好，公司高度重视创新研发，并持续完善“预防&治疗”产品布局，预防类管线人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗处于上市申报阶段，治疗类管线利拉鲁肽注射液、德谷胰岛素注射液处于上市申报阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700039131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0046","LU1064131003.USD","BK0196","LU1328615791.USD","LU2580892789.USD","BK0077","LU2580892862.HKD","BK0239","300122","159646","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622784736","title":"智飞生物：宸安生物的司美格鲁肽注射液（减重）正处于III期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2622784736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622784736?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:42","pubTimestamp":1774604528,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物03月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，26年3月20日司美格鲁肽专利到期，各大药厂都在争分夺秒的加快相关仿制药品上市，但他们的产品属于仿制药品，没有减重作用，也占领不了庞大的减肥市场！！！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700038429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU2580892862.HKD","LU1064130708.USD","LU1328615791.USD","BK0188","300122","BK0077","LU2148510915.USD","BK0046","BK0196","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622473168","title":"智飞生物：公司以“技术&市场”双轮驱动发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2622473168","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622473168?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:42","pubTimestamp":1774604526,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物03月27日在投资者关系平台上答复投资者关心的问题。投资者提问：现在很多媒体都把智飞当成生物制药板块的反面教材来宣传报道，当然公司本身也不争气，股价连跌6年，近日还在不断创出新低，害的很多投资者倾家荡产亏损超90%，这也是不争的事实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700038419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1064130708.USD","LU2580892789.USD","BK0046","BK0188","LU2580892862.HKD","LU2148510915.USD","LU1064131003.USD","BK0239","LU1328615791.USD","BK0077","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622786695","title":"智飞生物（300122）披露吸附破伤风疫苗进入Ⅰ/Ⅲ期临床试验公告，3月26日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786695","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622786695?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:10","pubTimestamp":1774534229,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，智飞生物报收于14.78元，较前一交易日下跌2.18%，最新总市值为353.8亿元。智飞生物当日发布公告称，公司全资子公司北京智飞绿竹生物制药有限公司研发的吸附破伤风疫苗已进入Ⅰ/Ⅲ期临床试验阶段。该疫苗用于预防破伤风，采用柱层析法纯化抗原，纯度更高，免疫原性更好，可满足成人及外伤高风险人群暴露后预防需求。临床试验将在重庆开展，采用随机、盲法、多中心、对照方式评价安全性和免疫原性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600043991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2580892862.HKD","BK0077","BK0188","LU2148510915.USD","LU1064131003.USD","BK0046","BK0196","BK0239","159646","LU2580892789.USD","300122","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621289093","title":"智飞生物（300122）披露吸附无细胞百白破（组分）b型流感嗜血杆菌（结合）联合疫苗进入Ⅰ期临床试验公告，3月24日股价上涨2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621289093","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621289093?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:23","pubTimestamp":1774362201,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，智飞生物报收于15.12元，较前一交易日上涨2.23%，最新总市值为361.94亿元。智飞生物于近日披露《关于公司吸附无细胞百白破（组分）b型流感嗜血杆菌（结合）联合疫苗进入Ⅰ期临床试验的公告》。该疫苗用于预防百日咳、白喉、破伤风及b型流感嗜血杆菌引起的疾病，采用单独纯化抗原组分技术，质量均一，可替代现有百白破疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400039965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0188","LU1328615791.USD","BK0196","BK0077","BK0239","LU2580892862.HKD","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","BK0046","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621745173","title":"股市必读：智飞生物（300122）3月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2621745173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621745173?lang=zh_cn&edition=full","pubTime":"2026-03-23 02:26","pubTimestamp":1774203973,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，智飞生物报收于15.66元，下跌1.51%，换手率1.14%，成交量16.17万手，成交额2.56亿元。董秘最新回复投资者： 请问董秘，子公司重庆精准生物的CAR-T产品近期是否取得重大突破，目前进展如何？今年1月，公司发布业绩预报，2025年全年亏损超130多亿元。当日关注点来自交易信息汇总：3月20日主力资金净流出1229.78万元，散户资金净流入1386.34万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300000812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU2580892789.USD","BK0077","BK0046","LU1064131003.USD","BK0239","LU1328615791.USD","LU2580892862.HKD","LU1064130708.USD","BK0196","300122","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620789640","title":"智飞生物：公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620789640","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620789640?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:45","pubTimestamp":1773996325,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)03月20日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问贵公司有没有鼻咽癌EB病毒疫苗的技术储备？智飞生物回复：您好，公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作，并获得相关发明专利。EBV疫苗处于临床前研发阶段，详情请关注公司的信息披露。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000028530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU2148510915.USD","LU1064130708.USD","LU2580892789.USD","LU1064131003.USD","BK0196","BK0077","300122","LU2580892862.HKD","BK0188","BK0046","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620374475","title":"智飞生物（300122）披露控股股东部分股份质押公告，3月17日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620374475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620374475?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:35","pubTimestamp":1773758115,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，智飞生物报收于16.28元，较前一交易日下跌0.73%，最新总市值为389.71亿元。公司于2026年3月17日披露《关于公司控股股东部分股份质押的公告》。公告显示，公司控股股东、实际控制人蒋仁生先生将其持有的20,100,000股公司股份进行质押，占其所持股份比例1.73%，占公司总股本比例0.84%，质押用途为股权类投资，质权人为重庆农村商业银行股份有限公司。蒋仁生及其一致行动人合计持股1,305,973,500股，本次质押后累计质押股份占公司总股本5.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0046","LU2148510915.USD","LU2580892789.USD","BK0077","BK0239","LU1064131003.USD","BK0188","LU1328615791.USD","LU2580892862.HKD","300122","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619453248","title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453248","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619453248?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:33","pubTimestamp":1773650038,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司近日收到全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)报告，由智飞龙科马自主研发的改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获得国家药品监督管理局药物临床试验批准通知书，同意本品在18周岁及以上人群中开展预防猴痘病毒引起的猴痘疾病的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU2580892862.HKD","LU2148510915.USD","BK0188","BK0046","LU1064131003.USD","BK0239","LU1064130708.USD","LU1328615791.USD","LU2580892789.USD","BK0077","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619160996","title":"智飞生物：截至2026年3月10日，公司普通股股东人数为123603","url":"https://stock-news.laohu8.com/highlight/detail?id=2619160996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619160996?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:12","pubTimestamp":1773393141,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)03月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止3月10日公司股东人数是多少？谢谢智飞生物回复：您好，截至2026年3月10日，公司普通股股东人数为123603，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300028952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU2148510915.USD","BK0046","BK0077","300122","BK0196","BK0188","LU1064131003.USD","BK0239","LU2580892789.USD","LU1064130708.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619607160","title":"智飞生物：宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2619607160","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619607160?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:12","pubTimestamp":1773393136,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)03月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，子公司宸安生物的司美格鲁肽注射液（减重）已进入临床III期试验阶段，是公司战略布局GLP-1及胰岛素药物管线的关键一步。目前进展如何？此药上市之后，与同款药品相比其最大竞争力是什么？在价格上是否比国外同类进口产品有更大优势？智飞生物回复：您好，宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组，公司的研发管线及其进展请持续关注公司的信息披露，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300028946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","LU1064130708.USD","LU2580892789.USD","BK0046","LU1328615791.USD","BK0188","BK0077","300122","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617968750","title":"“真金白银”显诚意：代表委员热议如何增强投资者“获得感”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617968750","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617968750?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:07","pubTimestamp":1772798828,"startTime":"0","endTime":"0","summary":"“投资与回报是资本市场的一体两面，我们将进一步完善上市公司分红激励约束机制，推动绩优公司结合实际出台中期分红、增加分红频次，提升投资者获得感。”3月6日下午，中国证监会主席吴清在十四届全国人大四次会议经济主题记者会上的这番讲话，迅速在两会代表委员中引发热议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603063664703183.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603063664703183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300607","002216","301033","BK4535","000723","002330","000630","06613","300769","BK4547","300122","300433","300666","002230","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617343685","title":"智飞生物：人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2617343685","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617343685?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:51","pubTimestamp":1772787077,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价连跌了6年，近期又创新低。公司一直将代理国外疫苗作为主要收入来源，公司没有自己的产品，而代理的国外疫苗营收大幅减少且开始巨额亏损。目前，公司人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600026730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2580892789.USD","LU1328615791.USD","BK0046","BK0188","LU1064131003.USD","LU2580892862.HKD","BK0077","LU1064130708.USD","BK0239","300122","LU2148510915.USD","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616312818","title":"智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2616312818","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616312818?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:22","pubTimestamp":1772526146,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，由控股子公司重庆宸安生物制药有限公司(简称“宸安生物”)研发的德谷胰岛素注射液申请生产注册获得国家药品监督管理局出具的《受理通知书》。公告显示，德谷胰岛素为长效胰岛素类似物，凭借独特的分子结构与作用机制，可在皮下形成可溶性多六聚体储库，实现平稳、持续、缓慢释放胰岛素，作用时间显著延长，具有降糖效果平稳、血糖变异性小、低血糖风险低、安全性良好、给药时间灵活等优点，每日一次皮下注射，适用于成人2型糖尿病治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU2580892862.HKD","BK0239","300122","BK0196","LU2580892789.USD","BK0046","LU1328615791.USD","LU1064130708.USD","BK0077","BK0188","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776107492421,"stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":-0.0433},{"period":"3month","weight":-0.2333},{"period":"6month","weight":-0.2554},{"period":"1year","weight":-0.3272},{"period":"ytd","weight":-0.1797}],"compareEarnings":[{"period":"1week","weight":0.028},{"period":"1month","weight":-0.0261},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0195},{"period":"1year","weight":0.2317},{"period":"ytd","weight":0.005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"123603人(较上一季度减少1.48%)","perCapita":"11442股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}